NASDAQ$OCGN
Ocugen Inc · Q2 2024 earnings
Q2 2024 earnings · · Investor relations
Briefing
Reported second quarter 2024 financial results and provided a business update.
Ocugen reported second quarter 2024 financial results, highlighting progress in their modifier gene therapy platform, including dosing patients in the OCU400 Phase 3 clinical trial and advancing OCU410 into Phase 2. They also received $32.6 million net cash from a public offering, extending their cash runway into Q3 2025.
- Actively dosing patients in OCU400 Phase 3 liMeliGhT clinical trial.
- OCU410 preliminary safety and efficacy data expected later this year.
- Expanded access program approved for OCU400.
- Received $32.6 million net cash from underwritten public offering of common stock.
Headline financials
Revenue & EPS history
Ocugen · Revenue · Quarterly
$1.14M
Forward guidance
Ocugen expects the cash runway to extend into the third quarter of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2024
-1.2%
Avg return
Earnings day
-2.7%
Avg return
5 days after
-3.7%
Avg return
30 days after
42%
19 / 45 earnings
Positive
+31.5%
Q1 2016
Best reaction
-27.5%
Q3 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.0% | +1.0% | -12.0% | |
| Q4 2025 | +5.4% | -10.8% | -3.8% | |
| Q3 2025 | -1.4% | -5.6% | -14.7% | |
| Q1 2025 | -2.3% | +0.9% | +53.8% | |
| Q4 2024 | -2.8% | -5.8% | +12.2% | |
| Q3 2024 | -0.9% | -11.3% | -19.4% | |
| Q2 2024 | +5.9% | +11.9% | -3.4% | |
| Q1 2024 | +8.3% | +5.5% | -16.0% | |
| Q4 2023 | -9.4% | -17.0% | +24.5% | |
| Q3 2023 | -6.3% | -2.6% | +1.3% | |
| Q2 2023 | -8.8% | +3.4% | -10.4% | |
| Q1 2023 | +3.3% | +7.3% | -32.1% | |
| Q4 2022 | +2.3% | +6.6% | -15.6% | |
| Q3 2022 | -3.3% | +15.7% | -8.5% | |
| Q2 2022 | +2.9% | +2.2% | -13.4% | |
| Q1 2022 | -12.3% | -19.7% | +0.4% | |
| Q4 2021 | +15.0% | +14.9% | +13.9% | |
| Q3 2021 | -11.4% | -8.4% | -41.3% | |
| Q2 2021 | +8.4% | +5.2% | -0.8% | |
| Q1 2021 | +6.2% | -10.1% | -9.0% | |
| Q4 2020 | -6.6% | -15.4% | -39.5% | |
| Q3 2020 | +1.4% | +3.8% | +8.0% | |
| Q2 2020 | -20.2% | -23.0% | -48.8% | |
| Q1 2020 | +0.0% | -5.2% | -24.2% | |
| Q4 2019 | -15.7% | -19.1% | -11.1% | |
| Q3 2019 | -27.5% | -50.6% | -64.7% | |
| Q2 2019 | +4.3% | -1.1% | +43.9% | |
| Q1 2019 | -4.7% | -8.8% | +54.9% | |
| Q4 2018 | -7.1% | -7.9% | +52.8% | |
| Q3 2018 | -4.7% | -17.8% | -9.3% | |
| Q2 2018 | +6.1% | +17.4% | -68.9% | |
| Q1 2018 | -2.3% | -17.3% | +7.3% | |
| Q4 2017 | -3.3% | -1.3% | -5.3% | |
| Q3 2017 | -5.2% | -9.8% | -9.9% | |
| Q2 2017 | +2.2% | -0.6% | +6.7% | |
| Q1 2017 | -1.2% | -1.2% | +0.0% | |
| Q4 2016 | +1.1% | -9.0% | +0.0% | |
| Q3 2016 | -3.7% | -9.4% | -23.8% | |
| Q2 2016 | +7.1% | +86.4% | +82.8% | |
| Q1 2016 | +31.5% | — | — | |
| Q4 2015 | +8.9% | — | — | |
| Q3 2015 | -16.6% | — | — | |
| Q2 2015 | +3.0% | — | — | |
| Q1 2015 | -2.5% | — | — | |
| Q4 2014 | +4.2% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro